IRIS
BERTINO, Gaetano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.200
EU - Europa 3.321
AS - Asia 2.280
SA - Sud America 460
AF - Africa 380
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 5
Totale 12.658
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.924
SG - Singapore 1.306
IT - Italia 964
IE - Irlanda 871
CN - Cina 808
UA - Ucraina 780
BR - Brasile 429
CI - Costa d'Avorio 269
CA - Canada 262
RU - Federazione Russa 223
SE - Svezia 104
DE - Germania 103
SN - Senegal 78
GB - Regno Unito 58
FR - Francia 43
VN - Vietnam 41
NL - Olanda 32
BE - Belgio 26
IN - India 23
AT - Austria 21
UZ - Uzbekistan 21
FI - Finlandia 20
CZ - Repubblica Ceca 19
TR - Turchia 19
CH - Svizzera 18
GR - Grecia 14
EU - Europa 10
IR - Iran 10
NG - Nigeria 10
AR - Argentina 9
MA - Marocco 9
PL - Polonia 9
HK - Hong Kong 8
MX - Messico 8
BD - Bangladesh 6
IQ - Iraq 6
LB - Libano 6
QA - Qatar 6
BG - Bulgaria 5
UY - Uruguay 5
ZA - Sudafrica 5
AU - Australia 4
CO - Colombia 4
KZ - Kazakistan 4
PE - Perù 4
PY - Paraguay 4
AO - Angola 3
HR - Croazia 3
PA - Panama 3
PK - Pakistan 3
RO - Romania 3
GA - Gabon 2
JP - Giappone 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
TN - Tunisia 2
VE - Venezuela 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
EC - Ecuador 1
ES - Italia 1
GH - Ghana 1
HN - Honduras 1
IM - Isola di Man 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
VI - Stati Uniti Isole Vergini 1
Totale 12.658
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.122
Dublin 867
Chandler 753
Singapore 750
Jacksonville 690
Chicago 394
Boardman 350
Abidjan 269
Nanjing 248
Lawrence 242
Andover 240
Cambridge 240
Toronto 214
Catania 180
Houston 137
Des Moines 126
Ashburn 120
Wilmington 99
San Mateo 98
Civitanova Marche 97
Dakar 78
Shenyang 75
Nanchang 69
Saint Petersburg 66
Hebei 54
Council Bluffs 53
Changsha 50
Milan 50
Bremen 46
Ottawa 46
Tianjin 43
Jiaxing 42
Mountain View 41
Los Angeles 35
The Dalles 34
Beijing 32
Palermo 32
Dong Ket 29
São Paulo 27
Brussels 26
Moscow 24
Rome 22
Norwalk 16
Belo Horizonte 15
Falls Church 15
Hefei 15
Mascalucia 15
Munich 14
Redmond 14
Brno 12
Foggia 12
Hanoi 12
Jinan 12
Leawood 12
Pune 12
Rio de Janeiro 12
Amsterdam 11
Kunming 11
Naples 11
Seattle 11
Washington 11
Abuja 10
Den Haag 10
Liberty Lake 10
Modica 10
Brasília 9
Helsinki 9
London 9
Porto Alegre 9
Florence 8
Gravina di Catania 8
Hangzhou 8
Hong Kong 8
New York 8
Ningbo 8
Turin 8
Zhengzhou 8
Frankfurt Am Main 7
Siracusa 7
Tashkent 7
Turku 7
Ardabil 6
Bari 6
Carlentini 6
Istanbul 6
Kiev 6
Trecastagni 6
Uberlândia 6
Ann Arbor 5
Augusta 5
Baghdad 5
Changchun 5
Ciudad Obregón 5
Dearborn 5
Guangzhou 5
Lausanne 5
Montevideo 5
Mumbai 5
Phoenix 5
Riposto 5
Totale 8.723
Salva come PNG Salva come JPEG
Nome #
Commentary on "Insertion of Totally Implantable Central Venous Access Devices by Surgeons" - What Is the Role of Surgeons When Implanting a Totally Implantable Venous Access Device to Prevent Immediate Complications? 138
Carbohydrate 19.9 Antigen Serum Levels in Liver Disease 137
Eterozigosi H36D per Emocromatosi in pazienti affetti da Steatoepatite e Epatite cronica da virus C 112
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirine 107
Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research 106
Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives 102
Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 99
Type II Mixed Cryoglobulinemia In Patients With Hepatitis C Virus: Treatment with Pegylated-Interferon and Ribavirin 97
Anorectal mucosal melanoma 96
Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer 94
Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study 94
Carotid Intima-Media Thickness and Liver Histology in Hemodialysis Patients with Non-Alcoholic Fatty Liver Disease 92
Possibile associazione di anemia normocromica con maggiore incremento delle molecole di adesione ICAM-2 e VCAM-1 in pazienti con cirrosi epatica: studio pilota 92
A study about mechanism of des-gamma-carboxy prothrombin’s production in hepatocellular carcinoma 90
Obesity and related diseases: an epidemiologic study in Eastern Sicily 89
D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis 89
Correction to: Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research (Internal and Emergency Medicine, (2022), 17, 3, (887-909), 10.1007/s11739-022-02967-1) 88
Eritropoietina nel trattamento dell'anemia secondaria a terapia con interferone peghilato e ribavirina 87
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. 86
High carbohydrate 19-9 antigen serum levels in patients with nonmelanoma skin cancer and primary occult cancer 85
Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis 84
Laparoscopic Reversal of Hartmann's Procedure: State of the Art 20 Years after the First Reported Case 83
Hepatocellular carcinoma serum markers 83
Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study 83
Folate levels in hepatocellular carcinoma patients with portal vein thrombosis 81
Rosuvastatin reduces non alcoholic fatty liver diseasa in patients with chronic hepatitis C treated with alpha-interferon and ribavirin 80
Evaluation of health status in patients with hepatitis c treated with and without interferon 79
Assessing degree of hepatic fibrosis in patients with chronic liver disease using gadoxetic acid-enhanced liver MRI: Preliminary results 79
Epatite cronica: un caso di sovrapposizione epatite autoimmune-epatite virale 78
Trattamento con peg-interferone e ribavirina nell’epatite cronica attiva C ed insorgenza di malattia celiaca: esiste una relazione ? 78
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 78
Homocysteine serum levels as prognostic marker of hepatocellular carcinoma with portal vein thrombosis 78
Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature 77
Giant cavernous liver hemangiomas: is it the time to change the size categories? 77
Trattamento dell'epatite cronica B, HBeAg negativa, con terapia di combinazione: Adefovir e Interferone-Pegilato alfa 2a vs Adefovir (Studio PAC: Peg Adefovir Combination) 75
Resveratrol in Patients with Minimal Hepatic Encephalopathy 75
Critical appraisal of the European Union Scientific Committee on Health, Environmental, and Emergency Risks (SCHEER) Preliminary Opinion on electronic cigarettes 74
Riduzione della densità minerale ossea volumetrica (pQCT) in pazienti con epatopatia cronica HCV-correlata: confronto con la misurazione DEXA 73
Systemic Therapies in Hepatocellular carcinoma: present and future 72
Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions 72
Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase -2 in patients with HCV-related chronic hepatitis. Relationship to histological features 72
ON-TREATMENT HBsAg DECLINE IS ASSOCIATED WITH SUBSEQUENT HBsAg REDUCTION IN HBeAg NEGATIVE CHRONIC HEPATITIS B 71
Carnitine Serum Levels in Frail Older Subjects 71
Circulating adhesion molecules in patients with virus-related chronic diseases of the liver 70
Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic epatiti C treated with pegylated interferon α and ribavirin 70
Hepatocellular Carcinoma: present and future 70
Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study 69
Circulating erytropoietin in microalbuminuric type 2 diabetic patients with normal renal function: a pilot study 68
Rare benign tumors of the liver: still rare? 68
A case of Overlap Syndrome:Autoimmune idiopatic hepatitis/pulmonary idiopatic hypertension 68
Aberrant sialylation in a patient with a HNF1α variant and liver adenomatosis 68
Incidence and causes of neonatal hyperbilirubinemia in a center of Catania 67
A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. 67
Totally Implantable Venous Access Devices: Efforts Are Needed to Standardize Procedures to Avoid Complications 67
A therapeutic education and medical support program improves adherence to therapy with peg-interferon plus ribavirin therapy and increases sustained virological response in patients with chronic hepatitis C 67
Chronic hepatitis C: This and the new era of treatment 66
Association Between Diabetes Mellitus, Hepatic Steatosis And Fibrosis In Chronic Hepatitis C Patients 66
Combined duodenal and pancreatic major trauma in high risk patients: can a partial reconstruction be safe? 66
Potential role of probiotics on colorectal cancer prevention 66
AIDS. Sindrome da Immunodeficienza Acquisita 65
A phase IIIb, 2X2 factorial, double blind study of 48 versus 96 weeks of peg-Interferon alpha 2a 180 micrg, with or without 24 weeks of Entecavir in adult patients with HbeAg negative chronic hepatitis B 65
Endozepine-4 levels are increased in hepatic coma. 65
Chronic anaemia and adhesion molecules in patients with liver cirrhosis. A preliminary report 64
Hepatocellular carcinoma and the risk of occupational exposure. 64
Current practice of chronic hepatitis B treatment in Southern Italy 64
Genotype-phenotype variable correlation in Wilson disease: clinical history of two sisters with the similar genotype 64
An unusual case of HBV reactivation in a patient with cholangitis and choledocho-lithiasis undergone to ERCP. A case report 64
Priority of the chronic HBV pathology in a samples of subjects suffering from liver disorder and hospitalized in the last triennium 63
Biochemical long-term outcomes in chronic hepatitis C patients treated with a twelve months course of alpha lymphoblastoid interferon 63
Reduction of volumetric bone mineral density in postmenopausal women with HCV-correlated chronic liver disease: a peripheral quantitative computed tomogtraphy (pQCT) study 63
Hepatocellular Carcinoma 63
Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection 62
Vaccinazione anti-epatite B: differenze della risposta immune con Hevac B Pasteur in rapporto all'età 62
Silybin supplementation during HCV therapy with pegylated interferon-a plus ribavirin reduces depression and anxiety and increases work ability 62
Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study 62
POST-LOAD INSULIN RESISTANCE IS AN INDEPENDENT PREDICTOR OF HEPATIC FIBROSIS IN DIABETIC PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE 62
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis 62
Does follow-up offer the best quality of life for patients affected by so-called 'giant' haemangiomas of the liver? 61
INFEZIONE DA HAV IN PAZIENTI CON EPATITE CRONICA HCV-CORRELATA 61
Respiratory and Cardiovascular Health Effects of e-Cigarette Substitution: Protocol for Two Living Systematic Reviews 61
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. 61
Acetyl-L-carnitine can slow the progression from prefrailty to frailty in older subjects. A randomized interventional clinical trial 60
Experience with vaccination against hepatitis B 60
Eritropoietina nel trattamento dell’anemia secondaria a terapia con interferone peghilato e ribavirina 60
Carbohydrate 19-9 antigen in chronic viral hepatitis without neoplasia is associated with the severity of liver disease 60
Polyunsaturated phosphatidylcholine (EPL) in the management of liver steatosis 59
The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases 59
What are the true advantages of devices for hepatic parenchimal transection in open surgery? 59
Telbivudine on-treatment HBsAg loss in naïve HBeAg negative chronic hepatitis B: A case report and brief review of the literature 59
Some patients with HCC havent't abnormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels 59
Behavior of alpha-1-antitrypsin in adults with chronic liver disease 58
La metalloproteinasi-2 è un marker indiretto di citonecrosi e fibrosi epatica nell’epatite cronica HCV-correlata 58
Pegylated-interferon and ribavirin therapy of HCV-related type II mixed cryoglobulinemia 58
Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases 57
Iron depletion and lifestyle modifications improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia 57
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment 56
ON-TREATMENT SERUM HBsAG DECLINE DURING TELBIVUDINE THERAPY IN NAÏVE CHRONIC HEPATITIS B: CASE REPORT 56
A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and Ribavirin 56
Visceral adipose tissue area as independent risk factor of elevated alanine aminotransferase 55
Studio trasversale sul portatore cronico di HBsAg 55
Totale 7.320
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.146
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.146
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020175 0 0 0 0 0 0 0 0 0 0 110 65
2020/20211.374 19 114 169 40 377 49 159 18 102 60 187 80
2021/20221.744 223 281 20 27 270 14 256 55 137 6 62 393
2022/20232.628 258 99 40 231 242 445 17 452 678 25 81 60
2023/20241.228 69 163 45 57 50 266 24 91 13 41 231 178
2024/20254.231 79 759 306 226 1.008 553 151 190 345 541 73 0
Totale 13.265